secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTIVION, INC. (AORT)
CIK:        0000784199
Form:       8-K
Filed at:   2026-05-18T11:06:12+00:00
Accession:  0001628280-26-035798
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artivion completes $135M acquisition of Endospan; adds Nexus aortic stent graft
-------------------------------------------------------------------------------

- Net purchase price of $135M funded via $150M delayed draw term loan.
- Contingent consideration up to $200M based on Nexus product performance, payable ~2 years post-close.
- FDA approved Premarket Approval for Nexus branched endovascular stent graft system in April 2026.
- Acquisition completes Artivion's aortic arch portfolio alongside AMDS and ARCEVO LSA devices.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/784199/000162828026035798/0001628280-26-035798-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/784199/000162828026035798/aort-20260518.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-035798

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer